• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OraSure Technologies Supports National HIV Testing Day

    6/27/24 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care
    Get the next $OSUR alert in real time by email

    BETHLEHEM, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions today announced its support of HIV testing initiatives taking place across the nation in recognition of National HIV Testing Day, held each year on June 27th. These testing initiatives will help encourage thousands of people across the U.S. to get tested for HIV.

    According to the Centers for Disease Control & Prevention, it is estimated that 1.2 million people in the United States are living with HIV, and approximately 14% do not know that they have it. Black/African American people disproportionately make up 40 percent of estimated HIV infections, also according to the CDC, even though they make up just 12 percent of the population.

    "Testing is critical to stemming the spread of HIV and our OraQuick® HIV Self-Test has empowered millions of people around the world to learn their HIV status, get connected to care, and subsequently live healthier lives," said Carrie Eglinton Manner, President and CEO of OraSure Technologies. "We have a longstanding history of empowering those at risk of contracting HIV through providing information about their health and are proud of our partnerships with community organizations across the country that promote HIV testing, especially for those communities who need it most."

    To highlight one such program, OraSure supplies its OraQuick® HIV Self-Test to the CDC's Together Take Me Home HIV self-testing program, which aims to distribute one million free HIV test kits over five years. The program has been successful in reaching individuals disproportionately impacted by HIV, including Black and Hispanic/Latino communities.

    The OraQuick® HIV Self-Test has been available direct to consumers in the U.S. since 2012. Since its launch, OraSure has been committed to providing consumers with access to critical information and connection to care. OraSure recently worked through the FDA to launch an updated and enhanced version of its OraQuick® HIV Self-Test. Aside from an updated look, this package delivers meaningful sustainability improvements through reduced packaging, including an expected 1,500 tons less paper and 450 tons less plastic usage annually, as well as increased shipping efficiencies, and lower transportation-associated emissions. The packaging now also contains even more robust educational material and linkage to care information, giving individuals information that they can use to make informed decisions, regardless of the test result.

    National HIV Testing Day is an annual campaign to raise awareness of the HIV/AIDS epidemic and to encourage Americans to get tested for the virus. OraSure provided OraQuick® HIV Self Tests to Greater Than HIV, a public information initiative of KFF, which will be used for free rapid HIV testing in more than 550 Walgreens stores today as part of National HIV Testing Day activities to encourage people to know their HIV status.

    About OraSure Technologies

    OraSure Technologies, Inc. ("OraSure") transforms health through actionable insight and powers the shift that connects people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. OraSure, together with its wholly-owned subsidiary, DNA Genotek Inc., is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure's portfolio of products is sold globally to clinical laboratories, hospitals, physician's offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

    Forward-Looking Statement

    This press release contains certain forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and various metrics, accruals and estimates. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: our ability to manufacture or have manufactured products in accordance with applicable specifications, performance standards and quality requirements; our ability to achieve sustainability improvements through reduced packaging; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; ability to meet increased demand for OraSure's products; and reduction or deferral of public funding available to customers. These and other factors that could affect our results are discussed more fully in our SEC filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2023, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements are aspirational and not guarantees or promises that goals, targets or projections will be met. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this press release and, except to the extent required by applicable law, OraSure Technologies undertakes no duty to update these statements.

    Investor Contact:

    Jason Plagman

    Vice President, Investor Relations

    [email protected]
    Media Contact:

    Amy Koch

    Director, Corporate Communications

    [email protected]


    Primary Logo

    Get the next $OSUR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSUR

    DatePrice TargetRatingAnalyst
    1/3/2023$5.00In-line
    Evercore ISI
    2/24/2022$15.00 → $12.00Buy
    Citigroup
    9/22/2021Outperform → Market Perform
    Raymond James
    8/4/2021$11.00 → $12.50Outperform
    Raymond James
    6/28/2021$12.00 → $11.00Outperform
    Raymond James
    More analyst ratings

    $OSUR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OraSure to Launch OraQuick™ HIV Self-Test in Canada

    BETHLEHEM, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its OraQuick™ HIV Self-Test has received a license from Health Canada for use in Canada. The OraQuick™ HIV Self-Test is a point-of-care rapid antibody test. It is Canada's first oral HIV self-test and detects antibodies for both HIV-1 and HIV-2, enabling individuals to find out their HIV status with a simple oral swab in as little as 20 minutes. The simplicity of the product makes it ideal for testing in a range of locations, including in the privacy of one's home, at the pharmacy, or at

    2/10/26 8:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

    BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure"

    2/9/26 4:15:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital

    BETHLEHEM, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OraSure" and "OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today confirmed that Altai Capital ("Altai") has nominated two candidates, including the fund's founder Rishi Bajaj, to stand for election to the Company's Board of Directors (the "Board") at its 2026 Annual Meeting of Stockholders. As previously announced, OraSure's Board has engaged extensively with Altai Capital. The Board interviewed Mr. Bajaj for potential service on the Board and ultimately decided to appoint an alternative candidate to serve as a director at OraSure. Since that time, Al

    1/15/26 1:00:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kenny John P. was granted 10,286 shares, increasing direct ownership by 7% to 163,608 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    12/19/25 4:08:48 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Boyd Steven Kyle was granted 34,632 shares (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    12/2/25 4:17:42 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Boyd Steven Kyle

    3 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    12/2/25 4:16:26 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gagliano Nancy J bought $4,982 worth of shares (2,100 units at $2.37), increasing direct ownership by 1% to 160,254 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    12/2/25 4:16:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Director Gagliano Nancy J bought $39,270 worth of shares (12,750 units at $3.08), increasing direct ownership by 16% to 91,524 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/3/25 9:08:13 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    President & CEO Eglinton Manner Carrie bought $100,027 worth of shares (28,670 units at $3.49), increasing direct ownership by 2% to 1,288,334 units (SEC Form 4)

    4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)

    3/3/25 9:07:25 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    SEC Filings

    View All

    SEC Form DEFA14A filed by OraSure Technologies Inc.

    DEFA14A - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    1/15/26 2:45:28 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    1/5/26 8:04:48 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form DEFA14A filed by OraSure Technologies Inc.

    DEFA14A - ORASURE TECHNOLOGIES INC (0001116463) (Filer)

    12/17/25 4:09:47 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI resumed coverage on OraSure with a new price target

    Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00

    1/3/23 8:07:55 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Citigroup reiterated coverage on OraSure Technologies with a new price target

    Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously

    2/24/22 8:34:18 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Technologies downgraded by Raymond James

    Raymond James downgraded OraSure Technologies from Outperform to Market Perform

    9/22/21 5:02:16 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/12/24 4:46:06 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by OraSure Technologies Inc.

    SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    11/4/24 1:18:55 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by OraSure Technologies Inc.

    SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)

    10/4/24 1:30:36 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Financials

    Live finance-specific insights

    View All

    OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th

    BETHLEHEM, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering fourth quarter 2025 financial results and certain business developments for 5 p.m. ET on February 25, 2026. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure"

    2/9/26 4:15:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Announces Third Quarter 2025 Financial Results

    BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2025. "In Q3 we delivered $27.1 million of revenue. While some of our customers continue to experience elevated levels of uncertainty related to funding for public health programs and research, we remain confident in our opportunities to return to growth in 2026, driven by diversification in our customer base and contributions from planned launches of new products in both rapid diagnostics and sample management solutions," said Carrie

    11/5/25 4:05:00 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th

    BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately one year. About OraSure Technolog

    10/29/25 7:30:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    $OSUR
    Leadership Updates

    Live Leadership Updates

    View All

    OraSure Technologies Appoints Steven K. Boyd to its Board of Directors

    Seasoned Investor with Deep Experience in the Healthcare and Medical Device Industries Brings Valuable Capital Markets Expertise and Investor Perspective  OraSure Board Has Added Three New Independent Directors in the Past Three Years Mara Aspinall to Step Down from the Board; Jack Kenny Appointed as Chair of the Board BETHLEHEM, Pa., Oct. 28, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of Steven K. Boyd to its Board of Directors, as a Class II director, effective immediately. The addition of Mr. Boyd is part of OraSure's ongoing Board refr

    10/28/25 4:22:03 PM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    OraSure Appoints Anne Messing as Chief Commercial Officer

    BETHLEHEM, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that Anne Messing has joined OTI as Chief Commercial Officer. Ms. Messing brings more than 25 years of commercial leadership experience across the healthcare industry, including in life sciences, diagnostics, and clinical laboratory services, with a proven track record of driving growth, building high-performing sales teams, and transforming strategic vision into demonstrable results and sustainable success. In her role at OTI, she will be responsible for Sales, Marketing, Strategic Alliance

    8/4/25 7:05:00 AM ET
    $OSUR
    Medical/Dental Instruments
    Health Care

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology